tiprankstipranks
Trending News
More News >
Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
Advertisement

Meiragtx Holdings (MGTX) AI Stock Analysis

Compare
459 Followers

Top Page

MGTX

Meiragtx Holdings

(NASDAQ:MGTX)

Rating:41Neutral
Price Target:
$7.00
▼(-8.97% Downside)
The overall stock score for Meiragtx Holdings is primarily influenced by its weak financial performance, characterized by persistent losses and high leverage. Technical analysis suggests a neutral to slightly bearish trend, while valuation metrics are unattractive due to negative earnings. The absence of earnings call data and corporate events means these factors do not impact the score.

Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)

Meiragtx Holdings Business Overview & Revenue Model

Company DescriptionMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
How the Company Makes MoneyMeiraGTx Holdings generates revenue primarily through collaborations and partnerships with pharmaceutical companies and research institutions. The company may receive milestone payments and royalties based on the commercial success of its gene therapy products developed in conjunction with these partners. Additionally, MeiraGTx is involved in the licensing of its proprietary technology and processes, which can also contribute to its revenue streams. As the company progresses its product candidates through clinical trials and toward commercialization, it anticipates that successful outcomes will lead to increased revenue from product sales and ongoing collaborations.

Meiragtx Holdings Financial Statement Overview

Summary
Meiragtx Holdings faces significant financial challenges with persistent losses and high leverage. While there are some positive signs in revenue growth and free cash flow improvement, the overall financial health is concerning due to negative profitability metrics and high debt levels.
Income Statement
35
Negative
Meiragtx Holdings shows a modest revenue growth rate of 9.88% TTM, but the company struggles with profitability as evidenced by negative net profit margins and EBIT margins. The gross profit margin has improved to 36.55% TTM, indicating some efficiency in cost management. However, the persistent negative EBIT and net profit margins highlight ongoing operational challenges.
Balance Sheet
30
Negative
The company's debt-to-equity ratio has increased to 2.44 TTM, indicating a high level of leverage which could pose financial risks. Return on equity remains negative, reflecting continued losses. The equity ratio is low, suggesting limited shareholder equity relative to total assets. These factors point to financial instability and potential risk.
Cash Flow
40
Negative
Free cash flow has shown growth of 22.27% TTM, which is a positive sign. However, operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some ability to cover net losses with free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue37.92M33.28M14.02M15.92M37.70M15.56M
Gross Profit10.07M9.49M14.02M7.20M29.83M15.56M
EBITDA-132.21M-121.69M-57.05M-115.95M-71.40M-53.68M
Net Income-157.50M-147.79M-84.03M-142.88M-71.98M-53.96M
Balance Sheet
Total Assets198.72M269.75M326.74M318.24M320.16M363.70M
Cash, Cash Equivalents and Short-Term Investments32.17M103.66M129.57M115.52M137.70M209.52M
Total Debt80.47M84.80M89.26M92.25M23.73M22.25M
Total Liabilities195.76M201.92M188.57M200.50M134.76M125.14M
Stockholders Equity2.96M67.83M138.18M117.74M185.40M238.56M
Cash Flow
Free Cash Flow-133.97M-109.45M-125.54M-118.06M-65.75M-100.99M
Operating Cash Flow-129.07M-104.50M-105.36M-73.10M-10.53M-63.97M
Investing Cash Flow-5.00M23.48M34.03M-44.96M-61.72M-37.02M
Financing Cash Flow61.36M54.53M84.02M95.20M1.71M82.73M

Meiragtx Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.69
Price Trends
50DMA
7.86
Negative
100DMA
6.89
Positive
200DMA
6.67
Positive
Market Momentum
MACD
-0.09
Positive
RSI
50.13
Neutral
STOCH
46.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 7.69 is below the 20-day moving average (MA) of 7.74, below the 50-day MA of 7.86, and above the 200-day MA of 6.67, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 50.13 is Neutral, neither overbought nor oversold. The STOCH value of 46.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.

Meiragtx Holdings Risk Analysis

Meiragtx Holdings disclosed 79 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Meiragtx Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$707.58M59.646.23%24.49%
66
Neutral
$631.57M49.763.33%85820.30%
54
Neutral
$972.79M-427.47%-48.25%33.77%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
49
Neutral
$800.74M91.25%16.75%14.72%
43
Neutral
$271.56M-120.15%-50.68%-76.38%
41
Neutral
$621.05M-379.53%366.84%-35.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MGTX
Meiragtx Holdings
7.69
3.67
91.29%
QURE
uniQure
17.95
12.58
234.26%
AKBA
Akebia Therapeutics
2.96
1.54
108.45%
TBPH
Theravance Biopharma
13.95
5.95
74.37%
CAPR
Capricor Therapeutics
6.74
2.54
60.48%
KROS
Keros Therapeutics
15.59
-38.29
-71.07%

Meiragtx Holdings Corporate Events

M&A TransactionsBusiness Operations and StrategyRegulatory Filings and Compliance
MeiraGTx Gains UK Approval for Hologen Transactions
Neutral
Jun 26, 2025

MeiraGTx Holdings plc has received the necessary clearances and approvals under the UK’s foreign direct investment laws for its proposed transactions with Hologen Limited, which were initiated on March 9, 2025. These transactions are anticipated to conclude in July 2025, potentially impacting the company’s operational and strategic positioning in the market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 05, 2025